The pneumonia (novel coronavirus disease, COVID-19) Epidemic in Wuhan is ravaging the world, and countries are concerned about the progress of vaccines. A study in Israel shows that vaccination with two doses of a vaccine developed by the American pharmaceutical company Pfizer in cooperation with the German biotech company BioNTech can reduce the rate of symptomatic infection by 94%, which is very effective in preventing the appearance of symptoms and serious illness in all age groups.
In order to stop the expansion of the epidemic, governments are committed to allowing the public to receive vaccinations, foreign media sources pointed out that Israel previously implemented the third Time the entire territory blockade, and hopes to vaccinate all people over 16 years of age by the end of March. Seventy percent of those vaccinated are middle-aged people in their 50s, and the vaccination rate for the elderly over 70 is nearly 100 percent.
According to a statement released by Clalit health Services, Israel’s largest healthcare provider, on the 14th, researchers tested 600,000 people who had received two doses of the Pfizer vaccine and found that compared to those who had not yet received the vaccine, those who had received two doses had a 94% reduction in symptoms. The results were equally valid for all ages, including those aged 70 and older. The study also showed a dramatic decrease in hospitalizations and serious illnesses among those over 55 years of age who received the vaccine.
Recent Comments